东北制药(000597) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥56,386,823.22, representing a significant increase of 39.83% year-on-year[9]. - Operating revenue for the reporting period was ¥1,937,952,713.26, reflecting a growth of 3.70% compared to the same period last year[9]. - The net profit after deducting non-recurring gains and losses was ¥54,496,060.97, a substantial increase of 83.21% year-on-year[9]. - Net profit for the current period was ¥61,474,686.58, compared to ¥41,094,187.86 in the previous period, indicating a significant increase of approximately 49.8%[62]. - The company reported a total profit of ¥72,348,856.23, compared to ¥44,786,546.46 in the previous period, an increase of approximately 61.8%[62]. - Net profit for the period was ¥181,630,350.75, compared to ¥161,436,155.31 in the previous period, indicating a growth of 12.57%[80]. - The company reported a total comprehensive income of ¥183,054,168.33, an increase from ¥162,349,834.50 in the prior period[84]. - The company recorded a tax expense of ¥37,379,307.02, compared to ¥11,099,037.08 in the previous period, showing a significant increase[80]. Earnings and Shareholder Returns - The basic earnings per share for the reporting period was ¥0.06, an increase of 20.00% compared to the same period last year[9]. - Basic and diluted earnings per share remained stable at ¥0.20, consistent with the previous period[84]. Cash Flow - The net cash flow from operating activities was -¥174,688,953.07, indicating a decline of 1,246.74% year-on-year[9]. - The net cash flow from operating activities was -406,842,339.08, a decrease from 535,859,896.60 in the previous period[104]. - Cash flow from operating activities generated ¥6,082,478,728.66, an increase from ¥5,246,346,767.03, representing a growth of about 16.0%[93]. - Cash inflow from financing activities totaled 2,411,835,159.47, down from 3,059,891,121.29, indicating a decrease of approximately 21.2%[107]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥12,480,596,444.96, an increase of 6.50% compared to the end of the previous year[9]. - The total liabilities increased to ¥8,628,568,887.86 from ¥8,125,906,330.73, representing a growth of approximately 6.2%[45]. - The balance of non-current liabilities due within one year at the end of the period is 916.11 million yuan, an increase of 2093% compared to the beginning of the year, mainly due to the reclassification of long-term payables related to a project financing[22]. - The total current liabilities amounted to ¥7,904,523,224.92, up from ¥6,651,377,374.80, which is an increase of about 18.8%[45]. - The total owner's equity rose to ¥3,852,027,557.10 from ¥3,592,837,914.30, indicating an increase of about 7.2%[48]. Cash and Cash Equivalents - The balance of cash and cash equivalents at the end of the period was ¥1,698,520,000, up 32% from the beginning of the year due to employee stock option contributions[20]. - The ending cash and cash equivalents balance was ¥1,015,327,770.92, down from ¥1,255,581,987.85, a decrease of approximately 19.1%[99]. - The ending balance of cash and cash equivalents was 400,747,593.49, compared to 794,027,825.23 at the end of the previous period, showing a decrease of about 49.6%[107]. Expenses - Research and development expenses decreased to ¥9,828,877.41 from ¥26,445,129.24, a reduction of approximately 62.8%[59]. - Sales expenses decreased to ¥502,607,262.69 from ¥527,265,520.34, a decline of about 4.7%[59]. - The company experienced a credit impairment loss of ¥6,963,574.01 during the period[80]. - Financial expenses decreased to ¥42,188,341.03 from ¥57,053,137.17, a reduction of about 26.0%[88]. Inventory and Current Assets - The balance of inventory at the end of the period is approximately 1.08 billion yuan, a decrease from approximately 1.27 billion yuan at the end of 2018[42]. - The inventory decreased to ¥381,391,190.15 from ¥538,985,086.93, representing a decline of approximately 29.2%[52]. - The total current assets increased to ¥2,616,730,105.50 from ¥2,458,601,873.77, indicating a growth of about 6.4%[52].